Verrica Pharmaceuticals Inc. VRCA
4.37
0.01
0.23%
as of 25 Sep
- Market cap
- $74.9M
- P/E
- 0.0×
Follow VRCA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
101.83% | (240.35%) | 1,414.20% | 473.29% | |
| (70.48%) | (35.33%) | (44.03%) | (83.02%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(342.65%) | (67.98%) | (98.48%) | (300.59%) | |
Average Days of Receivables |
86.77 | 55.37 | 76.74 | 133.50 | |
Free Cash Flow per Share |
(3.07) | (1.65) | (0.66) | (0.63) | |
Free Cash Flow |
(29.10) | (17.63) | (14.11) | (13.35) | |
Piotroski F-Score |
4.00 | 6.00 | 6.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(75.07%) | (31.74%) | (37.94%) | (81.89%) | |
Accounts Receivable Turnover |
8.32 | 13.00 | 5.52 | 2.13 | |
Accounts Payable Turnover |
2.09 | 1.73 | 2.14 | 2.18 | |
Inventory Turnover |
1.09 | 1.46 | 1.76 | 1.63 | |
Average Days of Payables |
217.08 | 219.78 | 205.61 | 136.80 | |
Days of Inventory on Hand |
315.56 | 237.18 | 185.08 | 231.44 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
24.34% | 24.89% | 28.07% | 48.21% | |
Selling, General and Administrative Expense of Revenue |
119.96% | 99.00% | 97.85% | 124.86% | |
Share Based Compensation of Revenue |
10.99% | 9.33% | 8.58% | 11.59% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.12 | 0.99 | 0.79 | 0.43 | |
Depreciation/Fixed assets |
3.75 | 3.74 | 4.02 | 4.38 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
3.25 | 3.34 | 1.74 | 1.42 | |
Operating CF per Share |
(3.07) | (1.65) | (0.66) | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(84.38%) | (50.27%) | (47.97%) | (102.84%) |
Columns are period end dates